Is Bromazepam Stronger Than Xanax? Potency Compared

Alprazolam (sold as Xanax) is considerably more potent per milligram than bromazepam (sold as Lexotan, Lectopam, and other brand names), but “stronger” and “more potent” are not the same thing in pharmacology, and the distinction matters. Milligram for milligram, alprazolam produces a larger anxiolytic effect: a typical equivalency puts roughly 3 to 6 mg of bromazepam as comparable to just 0.5 mg of alprazolam. That makes alprazolam somewhere around six to twelve times more potent by weight. Yet when both drugs are dosed appropriately for the same condition, they reduce anxiety to a similar degree. The real differences between them show up in how fast they work, how they affect the brain in overdose, and what happens when you try to stop taking them.

What “Potency” Actually Means Here

Potency in pharmacology refers to the amount of a drug needed to produce a given effect. A more potent drug is not necessarily a “better” or “stronger” drug in any practical sense; it just requires fewer milligrams. If you take 0.5 mg of alprazolam and 6 mg of bromazepam, you can end up in roughly the same clinical state. The confusion arises because people naturally assume a lower-dose pill must be hitting harder. In reality, manufacturers simply put less of the active ingredient in each tablet because less is needed. The pill size tells you nothing about how intense or long-lasting the effect will be at prescribed doses.

Where potency does matter is in accidental overdose, drug interactions, and the margin for error. A drug that works at sub-milligram doses leaves less room for dosing mistakes. That is one reason why alprazolam carries a higher overdose risk profile, as discussed below.

How They Compare for Anxiety Relief

A double-blind trial of 119 outpatients with moderate-to-severe anxiety compared alprazolam and bromazepam at flexible doses over four weeks. Anxiety scores on the Hamilton scale dropped by about 58% with alprazolam and 55% with bromazepam. Psychiatrists rated the treatment a success in roughly 83% of alprazolam patients versus 74% of bromazepam patients, and patients’ own ratings tracked similarly. Fewer side effects were recorded in the alprazolam group (97 events versus 120), though the difference in overall tolerability only approached statistical significance. The researchers concluded that alprazolam had a somewhat better balance of efficacy to side effects.¹

Those numbers are close enough that, for most people with generalized anxiety, either drug could be an appropriate choice. The gap is not large, and individual variation in how someone metabolizes each compound can easily flip the advantage one way or the other. A person who responds poorly to one benzodiazepine does not necessarily respond poorly to all of them, and clinicians often try switching within the class before abandoning it.

Receptor Binding and Why Alprazolam Hits Differently

Both drugs work by enhancing the activity of GABA, the brain’s main inhibitory neurotransmitter, at a specific type of receptor. But they do not bind to that receptor in exactly the same way or with the same strength. A computational study modeling how various benzodiazepines dock onto the GABA-A receptor predicted that alprazolam has the strongest binding affinity among the benzodiazepines tested, while bromazepam binds to different specific contact points on the receptor’s alpha and beta subunits.²

This difference in binding strength is part of why alprazolam can produce a more rapid, subjectively intense onset of anxiolytic and sedative effects at equivalent doses. It also helps explain alprazolam’s higher abuse potential. Drugs that bind tightly and act quickly tend to produce a more reinforcing subjective experience, which is the same pharmacological profile that makes a substance more habit-forming.

Speed of Onset

When you swallow a tablet, how quickly the drug reaches peak levels in your blood determines how soon you feel it working. A pharmacokinetic comparison found that standard bromazepam (and lorazepam) reached initial peak plasma concentrations about one to two hours after a dose, while a sustained-release formulation of alprazolam took roughly six hours to reach its peak plateau.³ That comparison involved the extended-release version of alprazolam, though, not the immediate-release form most people know as Xanax. Immediate-release alprazolam typically peaks within one to two hours as well, putting it in the same ballpark as bromazepam for speed of onset.

The practical takeaway is that if you are taking standard immediate-release tablets of either drug, you will feel both of them begin to work within about an hour. Extended-release alprazolam is deliberately designed to flatten and spread that peak, which reduces the intensity of the initial effect but provides more even coverage throughout the day.

Sedation, Driving, and Cognitive Impairment

All benzodiazepines impair cognitive and motor performance to some degree, but alprazolam appears to do so with particular severity. A randomized, placebo-controlled study measuring actual on-road driving performance found that alprazolam caused serious driving impairment: participants wove more within their lanes, rated their own driving as worse, felt less alert, and required more mental effort behind the wheel compared to placebo. The researchers concluded that alprazolam users should be warned against driving or operating dangerous machinery.⁴

Bromazepam also impairs psychomotor function, but its sedative profile tends to be somewhat milder at equivalent anxiolytic doses, partly because its lower receptor binding affinity translates into less acute central nervous system depression. An animal study comparing alprazolam, bromazepam, diazepam, and lorazepam across sedation, muscle relaxation, and anxiety tests found overlapping but distinct behavioral profiles among the four drugs, with the muscle-relaxing effects of alprazolam, bromazepam, and diazepam all increasing after repeated dosing.⁵ The clinical implication is that neither drug is safe to drive on, but alprazolam tends to cause more noticeable acute impairment, especially during the first few hours after a dose.

Overdose Risk

This is the area where the potency difference between the two drugs has real, dangerous consequences. In a large study of benzodiazepine overdose cases, alprazolam was significantly more toxic than other benzodiazepines. About 22% of alprazolam overdose patients were admitted to the ICU, which was roughly twice the rate compared to overdoses involving other benzodiazepines after adjusting for age, dose, gender, time since ingestion, and co-ingested drugs. Alprazolam overdose patients were also more likely to need the reversal agent flumazenil and more likely to require mechanical ventilation.⁶

Several factors contribute to this. Alprazolam’s higher milligram potency means a relatively small number of tablets can deliver a dangerous dose. Its tight receptor binding and rapid onset produce a steeper, more sudden depression of the central nervous system. And because alprazolam is one of the most commonly prescribed benzodiazepines worldwide, it appears in a disproportionate share of emergency department presentations, making it a significant public-health concern in the context of intentional and accidental overdose.

Bromazepam, while certainly not safe in overdose, has a wider therapeutic margin in part because it takes a larger absolute amount of the drug to produce the same depth of sedation. That does not make it harmless, but the statistical profile of overdose outcomes is less severe.

Withdrawal and Discontinuation

Both drugs can produce physical dependence, and stopping either one abruptly after regular use can cause withdrawal symptoms ranging from rebound anxiety and insomnia to, in severe cases, seizures. But the withdrawal profile is not identical for both.

A double-blind trial of 112 patients with generalized anxiety disorder tracked withdrawal difficulties during discontinuation of either extended-release alprazolam or bromazepam. In the alprazolam XR group, physicians rated withdrawal as absent in 60% of patients, mild in 20%, moderate in 16%, and severe in 4%. In the bromazepam group, withdrawal was absent in 46%, mild in 33%, moderate in 21%, and severe in none.⁷

The numbers tell an interesting story. More alprazolam XR patients had no withdrawal at all, but the ones who did have difficulty were more likely to hit the severe end. Bromazepam’s withdrawal was distributed more toward the mild-to-moderate range, with no patients experiencing severe withdrawal in that trial. This pattern aligns with what clinicians generally observe: alprazolam’s higher potency and faster onset create a sharper drop when the drug is removed, producing more intense (though sometimes shorter) withdrawal episodes. Bromazepam’s more gradual pharmacological profile tends to produce withdrawal that is more spread out and less acute. It is worth noting that this study used the extended-release form of alprazolam, which is specifically designed to smooth out the peaks and valleys that drive withdrawal; the immediate-release version might produce an even more difficult discontinuation profile.

Falls and Safety in Older Adults

Benzodiazepine use in older adults is a perennial concern because the drugs amplify the risk of falls, which can cascade into hip fractures, hospitalization, and loss of independence. A cross-sectional study in an elderly population found that benzodiazepine use in general was associated with about a 65% increase in the rate of recurrent falls, but the risk varied by which specific benzodiazepine was being used. Bromazepam was associated with a roughly 44% increase in falls, while some other benzodiazepines carried even higher risks.⁸

Alprazolam was not singled out with a separate statistic in that particular study, but the general finding applies across the class. For older adults, the choice between bromazepam and alprazolam is often less about which is “stronger” and more about whether a benzodiazepine is appropriate at all. Geriatric prescribing guidelines consistently recommend that benzodiazepines be used at the lowest effective dose for the shortest possible duration in older patients, regardless of which specific agent is chosen. When one is used, the fact that bromazepam is less potent per milligram can actually be an advantage: it gives clinicians more room to titrate in small increments without overshooting.

Why Bromazepam Is Common Outside the US but Not Inside It

If you live in the United States, you may never have heard of bromazepam. It is not approved by the FDA, so it is not commercially available in US pharmacies. In much of Europe, Latin America, Asia, and Canada, bromazepam is a standard-issue benzodiazepine prescribed for anxiety, pre-procedural sedation, and muscle tension. Alprazolam, by contrast, is available nearly everywhere and dominates prescribing in the US market.

This geographic divide creates a gap in the conversation. Americans researching benzodiazepines often encounter bromazepam only in the context of foreign prescriptions, online pharmacies, or travel. Europeans and Canadians, on the other hand, may be more familiar with bromazepam than with alprazolam. The drugs are genuinely interchangeable for many clinical purposes, but their different regulatory histories mean that head-to-head research is somewhat limited compared to, say, alprazolam versus diazepam or lorazepam, which are available in every major market.

When the Potency Comparison Misleads

People searching for which drug is “stronger” are usually trying to answer one of a few different practical questions, and the milligram-potency comparison answers only the narrowest version.

“Which will calm me down faster?” At standard doses, both reach peak blood levels within a similar window (one to two hours for immediate-release forms). Speed of onset is not where they differ much.
“Which is more dangerous?” Alprazolam carries a higher overdose toxicity risk and a sharper withdrawal profile. If danger is the question, alprazolam is the more concerning drug.
“Which works better for anxiety?” Clinical trials show comparable efficacy when both are dosed appropriately, with alprazolam holding a small and inconsistent edge.
“Which will I get more addicted to?” Alprazolam’s tighter receptor binding and more reinforcing subjective profile give it a higher abuse liability. Bromazepam is not free of dependence risk, but it is generally considered less prone to misuse.

The answer to “is bromazepam stronger than Xanax” is a clear no, if you are asking about milligram potency. But the more useful comparison depends on which of the questions above you are really asking. In clinical practice, the choice between them is driven less by abstract potency rankings and more by the patient’s specific anxiety pattern, their history with substance use, their age, and whether they need something for occasional panic or daily generalized anxiety.

Metabolism and Duration of Action

Alprazolam has an elimination half-life of roughly 6 to 12 hours in most adults, meaning the drug’s effects begin fading within that window and it needs to be taken two or three times a day for continuous coverage. Bromazepam has a broadly similar half-life, typically in the range of 8 to 20 hours depending on the individual’s liver function and age. Neither drug produces long-acting active metabolites the way diazepam does, which means both clear the system relatively quickly compared to the longest-acting benzodiazepines.

For the person taking either drug, this means the experience is roughly parallel in duration: take a dose, feel it within an hour, notice it fading four to six hours later, and need another dose if coverage is required around the clock. The main practical difference is that bromazepam’s somewhat longer average half-life can provide a slightly smoother tail-off at the end of each dose, reducing the “clock-watching” that some alprazolam users describe as they feel the drug wearing off before the next scheduled dose.

This tail-off pattern is not trivial. The subjective experience of feeling a drug leave your system between doses is one of the mechanisms that drives dose escalation and psychological dependence. A drug with a sharper drop creates a more noticeable contrast between “on” and “off” states, which reinforces the perceived need for the next dose. Bromazepam’s marginally gentler decline may contribute to its lower abuse profile, though the difference is modest and individual variation swamps population averages.

Drug Interactions Worth Knowing About

Both bromazepam and alprazolam are metabolized primarily by the liver, and both can interact dangerously with other substances that depress the central nervous system. Alcohol is the most common and most dangerous co-ingestant: combining either benzodiazepine with alcohol produces synergistic sedation that can suppress breathing. Opioids pose a similar risk, and the combination of benzodiazepines with opioids is a leading contributor to overdose deaths globally.

Alprazolam is metabolized predominantly by the CYP3A4 enzyme pathway in the liver. This means that drugs inhibiting CYP3A4, including certain antifungals like ketoconazole, some antibiotics like erythromycin, and grapefruit juice in large quantities, can slow alprazolam’s breakdown and raise its blood levels unpredictably. Bromazepam’s metabolism is less dependent on a single enzyme pathway, which can make it somewhat less susceptible to these specific drug interactions, though it is not immune to them.

If you are taking either drug and your doctor prescribes a new medication, the interaction check is important regardless of which benzodiazepine you are on. But alprazolam’s narrower reliance on one metabolic pathway makes it the more interaction-prone of the two.